Wednesday, May 22

7:00-8:00 Breakfast and Registration

8:00-8:15 Introduction and Welcome from the AES and ILAE
   Doug Coulter, PhD, 2nd Vice-President for AES
   Samuel Wiebe, MD, President, ILAE

SESSION I: EPILEPSY RESEARCH ROUNDTABLE UPDATE (2017/2018 Meetings)

Moderator: Jacqueline French, MD

8:15-8:35 Infant Epilepsy Trials
   Where Are We Now?
   Dennis Dlugos, MD

8:35-8:55 Grouping vs Splitting
   Should we Include More Than One Syndrome/More than One Seizure Type in our Clinical Trials?
   Nathan Fountain, MD

8:55-9:15 Beyond Seizures
   How do We Assess Impact of Treatments on the Full Spectrum of the Disease?
   Michael Sperling, MD

9:15-9:35 Combining Multiple Outcomes
   Looking at Multiple Outcomes of Disease in an Integrated Way
   Samuel Wiebe, MD

9:35-9:55 Discussion

9:55-10:20 Break

SESSION II: REGULATORY ISSUES

Moderator: Kimford Meador, MD

10:20-10:40 Monotherapy – Integrated Approach in US and Europe
   Jacqueline French, MD
10:40-11:00 EMA Update  
Emilio Perucca, MD, PhD

11:00-11:20 NIH Update for Treatment and Device Research and Development  
Brian Klein, PhD

11:20-11:40 Discussion

SESSION III: ORPHAN INDICATIONS AND CLINICAL TRIAL ISSUES
Moderator: Terrence O’Brien, MD

11:40-12:00 What Have We Learned from Recent Orphan Approvals?  
Rima Nabbout, MD

12:00 -12:20 Trials for Ultra-Orphans  
Are They Possible?  
Paul Goldberg, MB, ChB, PhD

12:20- 1:30 Lunch (Not included in registration)

1:30-1:40 Clinical Trials From “Then” to “Now” Through the Looking Glass  
Lloyd Knapp, PharmD

1:40-2:00 Reconsideration of Trial Methodology for Adjunctive RCT’s  
Are We Ready for a Change?  
Emilio Perucca, MD, PhD

2:00-2:20 EEG as a Primary End Point for Trials  
Jeffrey Buchhalter, MD, PhD

2:20-2:40 Electronic Seizure Diaries  
Do They Help or Hurt Seizure Counting in Trials?  
Gail Farfel, PhD

2:40-3:10 Panel: I Used an Electronic Seizure Diary and This is How it Went  
Gail Farfel, PhD, Kimberly Parkerson, MD, PhD  
Kevan VanLandingham, MD, PhD

3:10-3:30 Discussion

3:30-3:50 Break

SESSION IV: DEVICE SESSION
Moderator: Piero Perucca, MD, PhD

3:50-4:10 EF “My Seizure Gauge” Update, and How Can it Change Drug Development?  
Greg Worrell, MD, PhD
Thursday, May 23

SESSION V: GENETICS AND DRUG DEVELOPMENT

Moderator: Eric Segal, MD

8:15-8:35 Genetic Models for Drug Development. How Predictive are They?
Part 1: Stem Cells and Organoids
John Huguenard, PhD

8:35-8:55 Genetic Models for Drug Development. How Predictive are They?
Part 2: Rodent Models
Jennifer A. Kearney, PhD

8:55-9:15 Debate: Specificity and Sensitivity of Genetic Models
Dr. Huguenard, Dr. Kearney and Dr. Jack Parent

SESSION VI: PRECLINICAL

Moderator: Karen Wilcox, PhD

9:15-9:35 Everything Old is New Again: Do the “Standard” Screening Tests (MES, PTZ)
Have Any Place in Modern Drug Screening?
Steve White, PhD

9:35-9:55 The New NINDS Epilepsy Screening Program: Is it Getting Us to Better Therapies?
Karen Wilcox, PhD

9:55-10:15 Discussion

SESSION VII: ANTIPEILEPTOGENESIS AND DISEASE MODIFICATION

Moderator: Marc Dichter, MD, PhD

10:45-11:05 Accelerating the Development of Therapies for Anti-Epileptogenesis and Disease Modification Workshop – Briefing Update
Roy Twyman, MD
11:05-11:25 Repurposing Drugs for Antiepileptogenesis: A Combinatorial Approach
   Wolfgang Löscher, DVM, PhD

11:25 -11:45 Antiepileptogenesis Trial Post TBI Ready for Prime Time?
   Paul Vespa, MD

11:45-12:05 Contribution of Inflammation to Perpetuation of the Seizure Focus
   Annamaria Vezzani, PhD

12:05-12:30 Discussion

12:30-2:15 Lunch (Not included in registration)

2:15-5:30 SHARK TANK COMPETITION

   Aaron Bernstein, PhD, Advanced Scanners, Inc.

2:25-2:35 Virtual Reality Medical Simulation for the Management of Status Epilepticus
   Joshua Sherman, MD, Children’s Hospital of Los Angeles

Panelists:
   Moderator: Jacqueline French, MD
   Page Pennell, MD, Professor of Neurology, Harvard Medical School, Director of Research, Division of Epilepsy, Brigham and Women’s Hospital, Boston, Mass.
   May Liang, Co-Founder, General Counsel and Chief Financial Officer, OpenConcept Systems, Inc.
   Terrence O’Brien, MD, Professor of Medicine, Department of Neuroscience and Medicine, Monash University, Australia
   Tracy Dixon-Salazar, PhD, Director of Research and Strategy, LGS Foundation
   Timothy Feyma, MD, Gillette Children’s Specialty Healthcare

Finalists:
   EpiSAT: An EHR-Integrated Clinical Decision Support Tool for Detecting Seizure Risk
   Sharon Chiang, MD, PhD, UCSF

   Detecting Seizures With an Eye-Opening Solution
   Rachel Kuperman, MD, CEO, Eysz, Inc.

   Falling Down the Rabbit Hole of Medication Adherence
   Jody McNannay, Co-founder, Curadite, Inc.
Improving Patient Care Through VR
Matthew Musser, CEO and Founder, Seize the Wheel

Wearable for 24/7 Seizure Monitoring and Decision Support
Benjamin Vandendriessche, PhD, Byteflies

6:00 RECEPTION

2018 EPILEPSY FOUNDATION LIFETIME ACCELERATOR AWARD
RECIPIENT: MARTIN J. BRODIE, MD

Friday, May 24 PIPELINE

8:35-8:50 The Epilepsy Study Consortium
David Squillacote, MD

8:50-9:00 New Resources for the Community – Pipeline Tracker
Sonya Dumanis, PhD, Epilepsy Foundation

SESSION VIII: DRUG PIPELINE—PRE-CLINICAL

Moderator: Marc Dichter, MD, PhD

9:00-9:10 Harnessing the Therapeutic Potential of Commensal Microbes for the Treatment of Human Epilepsy
Paolo Baroldi, MD, PhD, Bloom Science, Inc.

9:10-9:20 Antisense Oligonucleotide Suppression of Glycogen Synthase 1 for the Treatment of Lafora Disease
Paul Goldberg, MB, ChB, PhD, Ionis

9:20-9:30 Translational EEG Biomarkers for AEDs, to Identify Therapeutic Potentials in Epilepsy and Other CNS Applications
Corine Roucard, PhD, Synapcell SAS

9:30-9:40 Development of a Human Stem Cell-Derived Inhibitory Interneuron Therapeutic to Treat Refractory Epilepsy
Cory Nicholas, PhD, Neurona Therapeutics, Inc.

9:40-9:50 Precision Medicine Platform for Therapeutic Discovery in Monogenic Epilepsies
Graham Dempsey, PhD, Q-State Biosciences.

9:50-10:00 Targeting Kv7.2/7.3 Activators for the Treatment of KCNQ2-NEE
Steven Dworetzky, PhD, Knopp Biosciences, LLC

10:00-10:10 Novel, Highly Selective mTORC1 Inhibitors for the Treatment of TSC
Stelios Tzannis MS, PhD, Aeonian Pharmaceuticals
10:10-10:15 **Tribute in Memory of Joseph D'Souza**
Henrik Klitgaard, PhD

10:15-10:25 **Padsevonil**
Henrik Klitgaard, PhD, UCB Biopharma SPRL

10:25-10:45 **Break**

**SESSION IX : DRUG PIPELINE—CLINICAL**

**Moderator:** Bernd Schmidt, MD, PhD

10:45-10:55 **Fenfluramine for the Treatment of Epileptic Encephalopathies**
Glenn Morrison, PhD, Zogenix, Inc.

10:55-11:05 **Update on Cannabinoid Clinical Development**
Kevan VanLandingham, MD, PhD, Greenwich Biosciences

11:05-11:15 **2DG for Treatment of Epilepsy and TBI: an Update**
Thomas P. Sutula, MD, PhD, NeuroGenomeX, Inc

11:15-11:25 **Staccato Alprazolam for Acute Treatment of Seizures**
Jouko Isojarvi, MD, PhD, Engage Pharmaceuticals, Inc.

11:25-11:35 **Libervant DBF (diazepam buccal film) for Acute Repetitive Seizures**
Michael Rogawski, MD, PhD, Aquestive Therapeutics

11:35-11:45 **Beyond Seizures: Clinical Study Program ANAVAX2-73 in Neurodevelopmental Diseases**
Christopher Missling, PhD, Anavex Life Sciences Corp

11:45-11:55 **Next Generation Rescue Therapy for Seizure Emergencies: DiazePen™ Auto-Injector Program Update**
Anh Nguyen, MD, Xeris Pharmaceuticals

11:55-1:20 **Lunch** (Not included in registration)

1:20-1:30 **TAK-935 (OV935) Phase 1b Adult DEE Study Results and Current Phase 2 Pediatric DEE, ARCADE and ELECTRA Study Designs**
Dimitrios Arkilo, MD, Takeda Pharmaceuticals

1:30-1:40 **An Update on Cenobamate**
William E. Rosenfeld, MD, SK LifeScience

1:40-1:50 **Biomarker-Stratified Phase 3 Study of Ganaxolone in PCDH19-Related Epilepsy**
Alex Aimetti, PhD, Marinus Pharmaceuticals, Inc.
CVL-865: A Great Foundation with a New Direction
Rachel Gurrell, Cerevel Therapeutics, LLC

Enabling Drug Delivery Technologies to Address Unmet Needs in Epilepsy
Adrian Rabinowicz, MD, Neurelis

Xenon Kv7 Potassium Channel Modulators
Ernesto Aycardi, MD, Xenon Pharmaceuticals, Inc.

A Patient-Centric Approach to Characterizing the Individual Placebo Response
Dominique Demolle, PhD, Tools4Patient

SESSION X: DEVICE PIPELINE
Moderator: Elinor Ben-Menachem, MD, PhD

Direct Delivery to the CNS, Using Implantable Long-Term Drug Infusion: Systems, for Severe Chronic Refractory Epilepsy
Dan Abrams, MD, Cerebral Therapeutics

Midazolam Needle Free Injector: a Breakthrough Rescue Therapy for Epileptic Patients
Baya Fodil, Crossjet

Real Life Epilepsy Monitoring – Setting New Standards with Ultra-Long-Term EEG Recordings
Jonas Duun-Henriksen, PhD, MSc, UNEEG Medical A/S

Update on Epitel's Long-Term EEG Seizure Monitoring Device, Epilog
Erin West, Epitel, Inc.

Personalized, Targeted Non-Invasive Neurostimulation Provides Meaningful Reduction in Seizure Frequency in Patients Not Responsive to Medications
Alexander Rotenberg, MD, PhD, Neuroelectrics

Protein Biomarkers for Diagnosing Epileptic Seizure
John Gledhill, Jr., PhD, Cognizance Biomarkers, LLC

Clinical Validation Roadmap of an EEG-Based and Extensible Wearable Device
Ben Vandendriessche, PhD, Byteflies

Embrace2 Update: Improved Seizure Detection, Remote Monitoring for Doctors, and FDA Clearance
Chelsea Trengrove, PhD, Empatica, Inc.

Closing Remarks